<![CDATA[Camrelizumab Plus Apatinib Demonstrates Efficacy in Refractory Chordoma]]>
Treatment with camrelizumab plus apatinib showcased antitumor activity with an acceptable toxicity profile in patients with refractory chordoma, according to results from a phase 2 investigator-initiated trial (ChiCTR2100042938) published in the Journal of …